Cargando…

TYMS 3′-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy that has the worst 5-year survival rate of all of the common malignant tumors. Surgery, chemotherapy, and/or chemoradiation remain the main tactics for PDAC treatment. The efficacy of chemotherapy is often compromised because of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emelyanova, Marina, Pokataev, Ilya, Shashkov, Igor, Kopantseva, Elena, Lyadov, Vladimir, Heydarov, Rustam, Mikhailovich, Vladimir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779442/ https://www.ncbi.nlm.nih.gov/pubmed/35056973 http://dx.doi.org/10.3390/pharmaceutics14010077

Ejemplares similares

Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes
por: Emelyanova, Marina, et al.
Publicado: (2022)

Association between 5’-UTR and 3’-UTR Polymorphisms of the TYMS Gene and Breast Cancer in Kurdish Women of Iraq
por: Mohamad, Kazhal Shekh
Publicado: (2021)

Preoperative CT-based detection of extrapancreatic perineural invasion in pancreatic cancer
por: Khristenko, Ekaterina, et al.
Publicado: (2021)

Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer
por: Junior, José da Silva Nogueira, et al.
Publicado: (2012)

Test Your Memory (TYM) and Test Your Memory for Mild Cognitive Impairment (TYM-MCI): A Review and Update Including Results of Using the TYM Test in a General Neurology Clinic and Using a Telephone Version of the TYM Test
por: Brown, Jeremy M., et al.
Publicado: (2019)

TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
por: Fu, Zhuo, et al.
Publicado: (2019)

Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
por: Shirasu, Hiromichi, et al.
Publicado: (2018)

Role of Key TYMS Polymorphisms on Methotrexate Therapeutic Outcome in Portuguese Rheumatoid Arthritis Patients
por: Lima, Aurea, et al.
Publicado: (2014)

Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine
por: Vitello, Stefano, et al.
Publicado: (2020)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

LHC prawdopodobnie ruszy w tym tygodniu
Publicado: (2009)

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients
por: Amirfallah, Arsalan, et al.
Publicado: (2018)

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
por: Dong, Si-Qi, et al.
Publicado: (2021)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Pancreatic cancer and FOLFIRINOX: a new era and new questions
por: Marsh, Robert De W, et al.
Publicado: (2015)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2019)

Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis
por: Balboa-Beltrán, Emilia, et al.
Publicado: (2015)

Genetic Polymorphisms of the TYMS Gene Are Not Associated with Congenital Cardiac Septal Defects in a Han Chinese Population
por: Zhao, Jian-Yuan, et al.
Publicado: (2012)

Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism
por: Wang, Bo, et al.
Publicado: (2016)

Association Between Genetic Polymorphisms In TYMS And Glioma Risk In Chinese Patients: A Case-Control Study
por: Yao, Li, et al.
Publicado: (2019)

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
por: Lin, Shaoyan, et al.
Publicado: (2019)

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
por: Chllamma, Muralidharan K, et al.
Publicado: (2016)

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
por: Fernandes, Gustavo dos Santos, et al.
Publicado: (2019)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma
por: Vary, Antonin, et al.
Publicado: (2021)

Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer
por: Li, Xujia, et al.
Publicado: (2023)

The Test Your Memory for Mild Cognitive Impairment (TYM-MCI)
por: Brown, Jeremy M, et al.
Publicado: (2017)

FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1–TYMS axis uncoupling in 5-FU resistance
por: Intuyod, Kitti, et al.
Publicado: (2018)

Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer
por: Choi, Young Hoon, et al.
Publicado: (2021)

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
por: Erstad, Derek J., et al.
Publicado: (2018)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma
por: Velez-Velez, Lisa M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vfm6hebabopqb790ddbj3udegq